Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

Francesca Corti,Vito Amoroso,Davide Campana,Maria Pia Brizzi,Francesco Panzuto,Ivana Puliafito,Natalie Prinzi,Massimo Milione,Monica Niger,Maria Antista,Alessandra Raimondi,Federica Morano,Michele Prisciandaro,Teresa Beninato,Filippo Pagani,Giovanni Randon,Iolanda Pulice,Maria Di Bartolomeo,Filippo de Braud,Sara Pusceddu

Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

2021

TPS4167Background: Well-differentiated (WD) NETs are a group of rare neoplasms with limited therapeutic options. New combinations of somatostatin analogs (SSAs) and investigational drugs are warran...

Keywords:

Somatostatin
Medicine
Oncology
Investigational Drugs
Neuroendocrine tumors
Internal medicine
Cabozantinib
Lanreotide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations